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Exosomes and ectosomes are membrane-bound nanobiological 
units released from most cell types into the extracellular milieu. 
Currently, they are distinguished mainly by their biogenesis, 
exosomes being released upon fusion of multi-vesicular bodies 
with the plasma membrane and ectosomes budding directly 
from it (1). Given the experimental difficulty to identify and/
or isolate pure populations of exosomes and ectosomes, here 
we will refer to them collectively as extracellular vesicles 
(EVs). The physiological functions of EVs are diverse (e.g., 
cell-cell communication, cellular differentiation, immunity, 
inflammation) (2-6). In cancer, aberrant activity of the export 
machinery results in the release of a number of key proteins 
and nucleic acids associated with EVs. These EVs can 
modify the normal cellular microenvironment by promoting 
the formation of the pre-metastatic niche, modulate and/
or interfere with the immunologic properties of bone 
marrow-derived multipotent mesenchymal stromal cells 
(MSCs), a major constituent of cellular microenvironment 
invaded by cancer cells, and interact with B cells to foster 
tumor-promoting humoral immunity, ultimately playing a 
fundamental role in cancer progression (2,7,8). 
In the Cell paper “Exosome RNA unshielding couples stromal 
activation to pattern recognition receptor signaling in cancer”, 
Nabet and colleague (9) bring to the limelight the relatively 
new concept of RNA unshielding, in particular for signal 
recognition particle (SRP) RNA, coupled with EV-mediated 
cell transfer. The importance of SRPs, highly conserved 
complexes of a 7S RNA and six proteins that bind to pattern 
recognition receptors (PRRs), has been recently recognized 
because of in-depth mechanistic investigation and for their 
potential role in cancer progression (10). Specifically, Nabet 
and colleagues (9) reported that unshielded RN7SL1 non-
coding (nc) SRP RNA transferred by activated stromal EVs 
to adjacent triple-negative breast cancer cells stimulated 
the viral RNA PRR RIG-I, resulting in enhanced tumor 
growth and a malignant phenotype. We propose for 
this EV-mediated mechanism the acronym EVAMR for 
EV associated molecular response. Their data reinforce 
previous studies on the role of EVs in the crosstalk between 
stromal cells and breast cancer cells (11). Cancer cells are 
not alone during the process of invasion. They live in a 
crowded environment where an intense bi-directional 
communication with “normal” cells is  incessantly 
occurring. Cancer-associated fibroblasts, endothelial cells, 
macrophages, immune-derived cells, and MSCs have been 
described to interact with malignant cells and are potentially 
able to affect the malignant phenotype. Similarly, 
melanoma-derived EVs from the primary tumor reportedly 
“educate” their environment to form a pro-tumorigenic 
niche and program bone marrow-derived progenitors at the 
pre-metastatic site to assume a proangiogenic phenotype, 
thereby enhancing metastatic dissemination (2). 
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The prevalence of ncRNA species distinct from miRNAs, 
in particular SRP RNA, found by Nabet and colleagues (9) 
in stromal cell-derived EVs released during co-culture with 
triple negative breast cancer cells, is surprising given the 
general consensus in the EV field on the prevalence of EV-
associated coding RNA and miRNA. EVs are composed 
of lipids, proteins, nucleic acids and other molecules. 
Among nucleic acids, miRNAs have been studied more in 
depth, with several groups reporting that miRNAs isolated 
from EVs are enriched relative to the miRNAome of the 
originating cells (12-16), indicating that RNA molecules 
are selectively incorporated into EVs. From the pioneering 
study of Valadi and colleagues (12), a number of studies 
have been published to date demonstrating that miRNA 
secretion by EVs is not only a mechanism whereby cells 
rapidly dispose of miRNAs in excess to maintain RNA 
homeostasis, but also a strategy for the horizontal transfer 
of RNAs (17). Today we know that miRNAs, independent 
from the cellular amount, are selectively retained within the 
cells or exported (18,19), often together with the molecular 
machinery required to induce a miRNA-mediated silencing 
so to “guarantee” their activity once they reached their 
destination (20). EV-associated miRNAs have clinical 
potential both as therapeutic targets and biomarkers for 
diagnosis and monitoring of several diseases (21). To date 
in the main EV data repository “Vesiclopedia” (www.
microvesicles.org), there are ~28,000 entries for mRNAs 
and ~5,000 entries for miRNAs, but no entries for other 
ncRNAs. Newcomers to the EV field searching the web 
for “ncRNAs” and “exosomes” will likely encounter as 
one of the first “hits” a misleading review titled “Non-
coding RNAs in EVs: New Players in Cancer Biology” 
(Curr Genomics 2015), where the authors devote the 
whole article to miRNAs, failing to discuss studies on the 
presence of other types of ncRNA in EVs. Intriguingly, 
most studies on the characterization of EV-associated RNA 
have employed microarray or real time quantitative PCR 
(qPCR) assays; but because of the inherent limitations of 
these technologies, mostly miRNAs and mRNAs have been 
detected. However, new exciting data demonstrate the 
ability of EVs to carry a multitude of other ncRNA families 
whose identification may provide a more accurate snapshot 
of the status of the parental cell.
The growing use of tools like next-generation sequencing 
and deeper analysis of EV content, in terms of nucleic acids, 
reveal that the majority of normal and cancer cells load 
different RNA species with a size distribution between 25 
and 700 nucleotides (nt) in EVs. Small size RNAs (<700 nt) 
were found in saliva and breast milk EVs (22). EVs released 
by human MSCs (23) were found to contain smaller RNA 
species (<500 nt in length), while the majority of RNA in 
immune cell derived EVs were reportedly shorter than 
200 nt (14). Even if different EV isolation methods may 
account for the size discrepancies among the small ncRNA 
families (24), miRNA, tRNA, rRNA, small nuclear RNA 
(snRNA), small nucleolar RNA (snoRNA) and piwi-
interacting RNA (piRNA) have been found in most studies 
(14,25). Intriguingly, the contradictory data concerning 
the relative percentage of small ncRNA in EVs, confirm 
the large heterogeneity in EV preparations (I) among the 
different parental cells; (II) in the same producing cell 
(22,26). Moreover, as shown by Nabet et al. (9), the various 
small ncRNA content in EVs is strongly conditioned by the 
micro-environment. 
The EV world is still in its infancy. The spatiotemporal 
fate of EVs in vivo is currently obscure (27), and their 
intracellular path as well as the targets of the EV-associated 
biomaterials are still elusive. Moreover, the distinction of 
sub-classes of exosomes and ectosomes is still unclear. A 
very high degree of EV heterogeneity is indicated by the 
observation that, although the cargo space of an individual 
vesicle is very limited, thousands of proteins and RNA 
species are usually identified in an EV preparation from 
a monoculture. A single cell can release EVs of varying 
biogenesis, size, and cargo and different cell types may 
produce distinct, cell or tissue-specific repertoires of EVs. 
The recent discovery by one of our labs of spathasomes, 
which are sub-nuclear compartments originating from 
subdomains of Rab7+ late endosomes and nuclear envelope 
invaginations and are able to deliver EV-derived biomaterials 
into the nuclear compartment (28), opens the possibility that 
EV ncRNAs are at least in part destined to the nucleus of the 
recipient cell. Interestingly, ncRNAs regulate gene expression 
at the nuclear level. In particular, SRP RNAs are produced at 
the nucleolar or peri-nucleolar level and complete SRPs are 
assembled at the same location (29). 
Bringing SRP RNA and other non-miRNA species of 
ncRNA into the field of EVs as new important molecular 
players invites many new important questions: (I) are the 
SRP RNAs depending on the different releasing stromal 
cells? For example, can the pathological invasion of 
endothelial cells during tumoral angiogenesis, resembling 
the physiological invasion occurring during inflammation, 
be affected by these ncRNAs? Although several evidences 
have indicated that EVs released from cancer cells or 
from stromal cells are involved in the modulation of 
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neoangiogenesis (30), no data are available on the quality 
of EVs released from co-culture of endothelial cells with 
cancer cells and on the ratio between the different types of 
ncRNA. The picture is further complicated by the evidence 
that oncogene activation alters secretion of ncRNA via EVs 
by modifying the interaction of AGO2 with endosomes (31). 
Moreover,  environmenta l  components  of  cancer 
development such as hypoxia or metabolic shifts may 
add another, still unknown, level of intricacy; (II) are the 
results from Nabet’s paper exploitable for other cancer 
histotypes and is this mechanism involved in metastatic 
niche formation and maintenance? Up to know only few 
papers have focused on this aspect of EV biology and triple-
negative breast cancer cells have been used as model. It will 
be interesting to investigate if similar mechanisms do exist 
in other deadly cancers as pancreatic cancer, colon cancer 
or in hematopoietic malignancies, where the critical role 
played by MSCs in the maintenance of malignancy and in 
drug-resistance phenotype is well established (32); (III) in 
addition to the direct contact activation of stromal cells, 
what is the role, if any, of cancer EVs on stromal cells? (IV) 
Is the high level of SRP RNA only present in co-culture 
EVs or also in single stromal or cancer cell cultures? (V) 
What is the relevance of stromal delivery of non-miRNA 
ncRNA to cancer cells of patients with aggressive tumors? 
Through the paper by Nabet and colleague (9) and the 
growing interest for EV-associated ncRNA in cancer, a very 
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